South Korea
· Delayed Price · Currency is KRW Oscotec Company Description
Oscotec Inc. operates as a biotechnology company, engages in the drug development, functional materials and related products, and dental bone graft material businesses.
It develops SKI-O-703, a SYK inhibitor that is in Phase 2 clinical trials to treat rheumatoid arthritis and idiopathic thrombocytopenic purpura; SKI-G-801, a selective FLT3/AXL inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia, as well as other solid tumors; and lazertinib, a 3rd generation EGFR inhibitor that is in Phase 3 clinical trials to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in Phase 1a/1b clinical trials for the treatment of Alzheimer’s disease.
The company also offers dental health products, such as bone graft comprising InduCera, BioCera-F, and SynCeraII; and membrane consisting of LysoGide and CollaGuide.
In addition, it provides functional ingredients comprises OPB for osteoporosis; AIF for arthritis; SGA that enhance bone growth; and PRF-K for perio diseases.
The company was formerly known as Oscotec Co., Ltd and changed its name to Oscotec Inc. in June 1999.
Oscotec Inc. was founded in 1998 and is headquartered in Seongnam, South Korea.
| Country | South Korea |
| Founded | 1998 |
| Industry | Orthopedic, Prosthetic, and Surgical Appliances and Supplies |
| Employees | 51 |
| CEO | Jeung-Keun Kim |
Contact Details
Address: A Building, Korea Bio Park Seongnam, 13488 South Korea | |
| Phone | 82 3 1628 7613 |
| Website | oscotec.com |
Stock Details
| Ticker Symbol | 039200 |
| Exchange | KOSDAQ |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Jeung-Keun Kim | Chief Executive Officer |